Filed: 8/14/2025ACC: 0000950123-25-008422
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 13 equity positions with a total reported market value of $461.38M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
13
Positions
$461.38M
Total AUM (reported)
33.88M
Total Shares
Allocation by class
COMMON STOCK$401.37M87.0%
COMMON SHARES$53.74M11.6%
ORDINARY SHARES$6.26M1.4%
Portfolio Concentration
Top 3$275.57M59.7%
4–10$175.41M38.0%
11–25$10.40M2.3%
Top 3 weight
59.7%
Top 10 weight
97.7%
Voting Authority Distribution
Total shares with voting rights: 33.88M
Sole
Full voting authority
33.88M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole13
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings13
Rows:
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$154.53M
33.49%
Sole
2.35M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$70.03M
15.18%
Sole
4.01M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares1.05M
TypeSH
Market value$51.02M
11.06%
Sole
1.05M
Shared
0.00
None
0.00
Zenas BioPharma, Inc
SOLEShares4.91M
TypeSH
Market value$47.59M
10.32%
Sole
4.91M
Shared
0.00
None
0.00
ORIC Pharmaceuticals, Inc.
SOLEShares4.51M
TypeSH
Market value$45.83M
9.93%
Sole
4.51M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares3.13M
TypeSH
Market value$42.32M
9.17%
Sole
3.13M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$21.99M
4.77%
Sole
6.53M
Shared
0.00
None
0.00
Oculis Holding AG
SOLEShares322.50K
TypeSH
Market value$6.26M
1.36%
Sole
322.50K
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$5.88M
1.27%
Sole
1.96M
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$5.53M
1.20%
Sole
3.33M
Shared
0.00
None
0.00
Oruka Therapeutics, Inc
SOLEShares430.33K
TypeSH
Market value$4.82M
1.05%
Sole
430.33K
Shared
0.00
None
0.00
KALA Bio, Inc.
SOLEShares598.94K
TypeSH
Market value$2.85M
0.62%
Sole
598.94K
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares747.75K
TypeSH
Market value$2.72M
0.59%
Sole
747.75K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $154.53M 33.49% | 2.35M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $70.03M 15.18% | 4.01M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 1.05M | SH | $51.02M 11.06% | 1.05M | 0.00 | 0.00 |
Zenas BioPharma, IncSOLE | Common Stock | 4.91M | SH | $47.59M 10.32% | 4.91M | 0.00 | 0.00 |
ORIC Pharmaceuticals, Inc.SOLE | Common Stock | 4.51M | SH | $45.83M 9.93% | 4.51M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 3.13M | SH | $42.32M 9.17% | 3.13M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $21.99M 4.77% | 6.53M | 0.00 | 0.00 |
Oculis Holding AGSOLE | Ordinary Shares | 322.50K | SH | $6.26M 1.36% | 322.50K | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $5.88M 1.27% | 1.96M | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $5.53M 1.20% | 3.33M | 0.00 | 0.00 |
Oruka Therapeutics, IncSOLE | Common Stock | 430.33K | SH | $4.82M 1.05% | 430.33K | 0.00 | 0.00 |
KALA Bio, Inc.SOLE | Common Stock | 598.94K | SH | $2.85M 0.62% | 598.94K | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 747.75K | SH | $2.72M 0.59% | 747.75K | 0.00 | 0.00 |